Toth Financial Advisory Corp Grows Position in Krystal Biotech, Inc. $KRYS

Toth Financial Advisory Corp raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 75,083.3% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,511 shares of the company’s stock after purchasing an additional 4,505 shares during the period. Toth Financial Advisory Corp’s holdings in Krystal Biotech were worth $1,677,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of KRYS. UMB Bank n.a. increased its holdings in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after buying an additional 37 shares during the last quarter. Optimize Financial Inc raised its position in Krystal Biotech by 1.4% during the 4th quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after purchasing an additional 40 shares in the last quarter. Regal Investment Advisors LLC raised its holdings in shares of Krystal Biotech by 1.0% in the fourth quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock valued at $1,075,000 after acquiring an additional 44 shares in the last quarter. Torray Investment Partners LLC lifted its position in shares of Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock worth $3,108,000 after purchasing an additional 47 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its holdings in Krystal Biotech by 0.9% during the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock worth $1,537,000 after buying an additional 53 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Krystal Biotech

In other news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 51,000 shares of company stock worth $16,278,020 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Citigroup increased their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Chardan Capital upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Bank of America increased their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Finally, Evercore reissued an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

Krystal Biotech Stock Down 1.7%

NASDAQ:KRYS opened at $351.46 on Friday. The company has a fifty day simple moving average of $348.64 and a two-hundred day simple moving average of $304.16. Krystal Biotech, Inc. has a 52 week low of $136.73 and a 52 week high of $382.54. The company has a market cap of $10.40 billion, a price-to-earnings ratio of 44.04 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, analysts expect that Krystal Biotech, Inc. will post 7.48 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.